文献速递瓣膜外科先天性心脏病外科

生物瓣与同种移植物肺动脉瓣置换术后抗凝治疗的影响

Impact of Anticoagulation Therapy After Bioprosthetic and Homograft Pulmonary Valve Replacement.
PubMed 文献 · Ann Thorac Surg · 2025-01-17

该回顾性研究纳入2015年1月至2021年4月在波士顿儿童医院接受生物瓣或同种移植物肺动脉瓣置换或右心室-肺动脉管道置换的531例患者,随访中位1.16年,其中130例接受抗凝治疗。

要点

  • 抗凝组瓣膜功能障碍率9%对非抗凝组15%,差异无统计学意义。
  • 抗凝组早期大出血率3.4%对2.4%,组间无差异。

核心结论

  • 生物瓣或同种移植物肺动脉瓣置换术后抗凝治疗看似安全,与大出血无关联,但需更长期随访评估瓣膜耐久性。

研究设计与样本

  • 回顾性研究,纳入2015年1月至2021年4月波士顿儿童医院531例接受直径>15 mm生物瓣或同种移植物肺动脉瓣置换或右心室-肺动脉管道置换的患者。
  • 按抗凝状态分组比较,采用基于抗凝治疗的倾向评分校正的多变量Cox和logistic回归分析。
  • 中位随访1.16年,130例接受抗凝治疗。

主要发现

  • 1年、3年、5年免于再干预率分别为99%、92%、86%。
  • 抗凝组18次出血事件中仅1次(6%)发生于开始抗凝之后。

临床怎么用

  • 现有证据不支持以改善早期结局为目的常规抗凝,亦未显示大出血风险增加。
  • 抗凝决策需个体化权衡,中期至长期瓣膜耐久性获益尚待随访证实。

局限性

  • 回顾性单中心设计,中位随访仅1.16年,不足以评估中长期瓣膜耐久性。
  • 抗凝组仅130例,事件数有限,统计效能可能不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effect of anticoagulation on early postoperative outcomes after pulmonary valve replacement (PVR) with bioprosthetic valves and homografts is not yet defined. We hypothesized that short-term anticoagulation would be associated with improved valve durability. METHODS: Patients undergoing PVR or right ventricle-to-pulmonary artery conduits with a bioprosthetic or homograft valve >15 mm in diameter between January 2015 and April 2021 at Boston Children's Hospital were retrospectively compared by anticoagulation status. Survival, postoperative echocardiographic data, and the incidence of pulmonary valve reintervention and prosthetic valve dysfunction were compared using multivariable Cox and logistic regression analyses adjusted for a propensity score based on anticoagulation therapy. RESULTS: Among 531 patients with a median follow-up of 1.16 years, 130 received anticoagulation therapy. Freedom from reintervention was 99%, 92%, and 86% at 1, 3, and 5 years, respectively. Adjusted for propensity score, there was no association between reintervention and anticoagulation (hazard ratio, 0.78; 95% CI, 0.18-3.47; P = .75). The propensity score-adjusted rates of valve dysfunction were 9% in anticoagulated patients and 15% in non-anticoagulated patients (odds ratio, 0.54; 95% CI, 0.18-1.56; P = .25). There was no difference in early major bleeding rates between groups (3.4% vs 2.4%, P = .59) or in other postoperative outcomes. Only 1 of 18 (6%) of all bleeding events in the anticoagulated group occurred after starting anticoagulation. CONCLUSIONS: Anticoagulation therapy appeared safe with no association with major postoperative bleeding. However, additional follow-up is necessary to assess its impact on midterm to long-term valve durability after PVR.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Reed AK, Sleeper LA, Roy N, et al. Impact of Anticoagulation Therapy After Bioprosthetic and Homograft Pulmonary Valve Replacement. Ann Thorac Surg. 2025. PMID: 39828075. doi:10.1016/j.athoracsur.2024.12.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。